Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

DNA study sheds light on myxoma resistance
Australia released myxomatosis in 1950 to tackle the burgeoning rabbit population.
Modern rabbits compared with specimens from before 1950s outbreak

An unprecedented rabbit DNA study has shed light on how rabbits have acquired resistance to myxomatosis.

Research led by the University of Cambridge and the CIBIO Institute in Porto looked at DNA from nearly 200 rabbits spanning 150 years and thousands of miles.

The team sequenced nearly 20,000 genes to pinpoint mutations since the myxomatosis pandemic in the 1950s.

According to findings published in the journal Science, modern rabbits in the UK, France and Australia, have acquired resistance to the myxoma virus through the same genetic changes. They also discovered that this process relied on lots of small mutations in different genes, rather than big changes in single genes.

Findings also suggest the protein that helps rabbits fight myxoma, also has an antiviral effect on an unrelated virus, vesicular stomatitis.

Miguel Carneiro, from CIBIO said: “While battling myxoma, rabbits may have increased their resistance to other viruses including, perhaps, rabbit haemorrhagic disease which is killing so many animals right now.”

Australia released myxomatosis in 1950 to tackle the burgeoning rabbit population, which was impacting the country’s native plants and animals. It is thought that the European rabbit was introduced to the country in the 1850s and within a century the population grew to hundreds of millions.

Within three months of releasing myxomatosis, it had spread 2,000km and killed 99 per cent of infected animals. It was illegally introduced to France in 1952 and spread to the UK in 1953, with similarly devastating consequences in all three countries.

Myxoma continues to present a serious threat to rabbits. Lead author Dr Joel Alves said: “Viral evolution appears to be finding ways to counter the genetic adaptations which we’ve observed. Recent, more virulent recent strains of myxoma virus, have been found to be extremely immunosuppressive. So the arms race goes on.”

As rabbit populations collapse across the UK and mainland Europe, researchers said the findings could provide clues to the future of the species.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.